These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37882942)
1. Zuranolone: First Approval. Heo YA Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942 [TBL] [Abstract][Full Text] [Related]
2. First Oral Treatment Specific for Postpartum Depression. Blakely KK Nurs Womens Health; 2024 Aug; 28(4):315-318. PubMed ID: 38768648 [TBL] [Abstract][Full Text] [Related]
3. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA Sharma R; Bansal P; Saini L; Sharma N; Dhingra R Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651 [TBL] [Abstract][Full Text] [Related]
5. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis. Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653 [TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. Frieder A; Fersh M; Hainline R; Deligiannidis KM CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145 [TBL] [Abstract][Full Text] [Related]
7. Zuranolone for the Treatment of Postpartum Depression. Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938 [TBL] [Abstract][Full Text] [Related]
8. Brexanolone: First Global Approval. Scott LJ Drugs; 2019 May; 79(7):779-783. PubMed ID: 31006078 [TBL] [Abstract][Full Text] [Related]
9. Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon. Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan SF Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110983. PubMed ID: 38412941 [TBL] [Abstract][Full Text] [Related]
10. Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression. Hitt EM Clin Ther; 2024 May; 46(5):433-438. PubMed ID: 38697873 [TBL] [Abstract][Full Text] [Related]
11. Zuranolone (Zurzuvae) - An oral drug for postpartum depression. Med Lett Drugs Ther; 2023 Dec; 65(1692):201-203. PubMed ID: 38133592 [No Abstract] [Full Text] [Related]
12. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression. Barnes KN; Vogl CM; Nelson LA Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder. Meshkat S; Teopiz KM; Di Vincenzo JD; Bailey JB; Rosenblat JD; Ho RC; Rhee TG; Ceban F; Kwan ATH; Cao B; McIntyre RS J Affect Disord; 2023 Nov; 340():893-898. PubMed ID: 37557991 [TBL] [Abstract][Full Text] [Related]
14. An update on approved and emerging drugs for the treatment of postpartum depression. Çulcu EA; Demiryürek Ş; Demiryürek AT Ideggyogy Sz; 2024 Jul; 77(7-8):227-235. PubMed ID: 39082257 [TBL] [Abstract][Full Text] [Related]
15. Redefining Postpartum Depression Treatment: The Clinical Potential of Zuranolone. Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan S Asian J Psychiatr; 2024 Jan; 91():103849. PubMed ID: 38056137 [No Abstract] [Full Text] [Related]
16. Zuranolone and its role in treating major depressive disorder: a narrative review. Ali M; Ullah I; Diwan MN; Aamir A; Awan HA; Waris Durrani A; Qudrat QU; Shoib S; De Berardis D Horm Mol Biol Clin Investig; 2023 Jun; 44(2):229-236. PubMed ID: 36848317 [TBL] [Abstract][Full Text] [Related]
17. Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid) Martinez Botella G; Salituro FG; Harrison BL; Beresis RT; Bai Z; Blanco MJ; Belfort GM; Dai J; Loya CM; Ackley MA; Althaus AL; Grossman SJ; Hoffmann E; Doherty JJ; Robichaud AJ J Med Chem; 2017 Sep; 60(18):7810-7819. PubMed ID: 28753313 [TBL] [Abstract][Full Text] [Related]
18. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders. Walkery A; Leader LD; Cooke E; VandenBerg A Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503 [TBL] [Abstract][Full Text] [Related]
19. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials. Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of neuroactive steroids with novel pharmacophore at C-21 let identify a compound with advantageous PK profile and higher EC Ma M; Xu H; Ye L; Li C; Zhu H; Jiang W; Wang W; Yang H; Yang Y; Wang Y; Tian J Eur J Med Chem; 2024 Oct; 276():116602. PubMed ID: 38971049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]